GSK's COPD Triple Combo To Challenge Chiesi's Trimbow In EU
Executive Summary
GSK's closed triple combination for COPD, Trelegy, is expected to get a green light for approval in Europe on Friday – but the product will be fighting for market share against Chiesi's triple combination Trimbow, which has a head start.
You may also be interested in...
Not Just Herceptin Biosimilar: Additional 12 Drugs Set For EU Marketing Approval After CHMP Nod
New treatments for plaque psoriasis and ovarian and prostate cancer join the first Herceptin biosimilar and several other products in garnering recommendations for EU marketing approval at September's meeting of EMA's key scientific committee, the CHMP. No decision was taken on Roche’s new MS drug, Ocrevus, and earlier negative opinions of three other products were upheld.
Snapshot: April Highlights
A selection of articles you might have missed from April 2022, including exclusive interviews, an in depth look at the impact of COVID-19 on clinical trial trends, and the latest Rising Leaders series.
Transforming Patient Engagement At Novartis
Rising Leader Yolanda Tibbe, Novartis’s head of new commercial partnerships in Germany, talks about transformation at the Swiss big pharma and how to put ‘patients as customers’ thinking into action.